STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources ...
STONY BROOK, N.Y.--(BUSINESS WIRE)--LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its ...
LineaRx intends to develop and out-license the technology as an early cancer diagnostic, and a prognostic to follow the course of contemporary cancer therapies including such redirected cell therapies ...
STONY BROOK, NY / ACCESSWIRE / July 18, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its ...
Tumor Reduction Demonstrated in Vivo Using Two Linear DNA Vaccines in Animal Models Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the ...
– LineaRx Functional iCTC Capture Assay Will be Used by TYME to Monitor iCTC Counts for Trial Participants – Under the terms of the Agreement, TYME has the option to purchase from the Company up to ...
BNB Plus announced that following a strategic restructuring and realignment of resources implemented earlier this year, its LineaRx subsidiary has significantly reduced its costs. Based on its reduced ...
Applied DNA Sciences Inc ( (APDN)) has released its Q3 earnings. Here is a breakdown of the information Applied DNA Sciences Inc presented to its investors. Take advantage of TipRanks Premium at 50% ...
Applied DNA Sciences Inc. ("Applied DNA" or the "Company") announced today that LineaRx, Inc. ("LineaRx"), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results